Literature DB >> 17606205

The model for end-stage liver disease comes of age.

Richard B Freeman1.   

Abstract

The care of patients who have chronic liver disease has evolved considerably since the Model for End-stage Liver Disease (MELD) was first described 6 years ago. This article traces the progress in liver allocation and clinical liver disease research that includes the MELD score and highlights the management of areas in which MELD and the principles underlying MELD enhance the clinician's ability to understand better the patient who has chronic liver disease.

Entities:  

Mesh:

Year:  2007        PMID: 17606205     DOI: 10.1016/j.cld.2007.04.005

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  5 in total

Review 1.  Transplant benefit for patients with hepatocellular carcinoma.

Authors:  Alessandro Vitale; Michael Volk; Umberto Cillo
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 2.  Model for end-stage liver disease: end of the first decade.

Authors:  Sumeet K Asrani; W Ray Kim
Journal:  Clin Liver Dis       Date:  2011-10-01       Impact factor: 6.126

Review 3.  Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit.

Authors:  Alessandro Vitale; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-21

Review 4.  Model for end-stage liver disease score and MELD exceptions: 15 years later.

Authors:  Sumeet K Asrani; Patrick S Kamath
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

5.  Health-related quality of life and survival in liver transplant candidates.

Authors:  Rajasekhar Tanikella; Steven M Kawut; Robert S Brown; Michael J Krowka; Jenna Reinen; Chandrasekhar R Dinasarapu; James F Trotter; Kari E Roberts; Mustafa A Mohd; Donna K Arnett; Michael B Fallon
Journal:  Liver Transpl       Date:  2010-02       Impact factor: 5.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.